ESPN 51th Annual Meeting

ESPN 2018


 
POSSIBILIIES OF CURRENT ANTI-RELAPSING TREATMENT OF URINARY TRACT INFECTIONS IN CHILDREN
DMYTRO IVANOV 1

1- SHUPYK NATIONAL MEDICAL ACADEMY OF POSTGRADUATE EDUCATION KIEV, UKRAINE
 
Introduction:

 

The Guidelines of the European Association of Urology (2018) recommend antibiotic and immunologic preventive treatment of recurrent urinary tract infections.

Material and methods:

 

A prospective, open-label, randomized, parallel-group study was conducted in 22 children aged 4 to 15 years old with recurrent urinary tract infections in order to establish the efficacy of industrially manufactured pentavalent vaccine. The experiment group included 28 children of similar age who received Uro-Vaxom vaccination within 6 months. Patients in both groups also received anti-relapse treatment with a single dose of urinary antiseptic nocte. The control group consisted of 33 children who had not received urinary antiseptic and vaccination after the treatment of urinary tract infections. The study duration was 18 months.

Results:

 

By the end of the study, the relapse-free disease progression was observed in 87 % (19 children) cases from the first group who had received pentavalent vaccine (Urivac). The relapse-free disease progression in the group that received monovalent Uro-Vaxom was observed in 72 % of cases (20 children) (OR = 2.5; Fishers exact test (two-tailed) – 0.30622, P > 0.05, the minimum value of expected event – 4.84). The relapse-free disease progression was observed in 13 children (40 %) who had not received urinary antiseptic nocte and vaccination (p ≤ 0.05, OR = 0.26 with a group of pentavalent vaccine). 15 % increase in efficacy during the use of pentavalent vaccine was obtained by elimination of Pseudomonas aeruginosa and Enterococcus faecalis.

Conclusions:

 

Pentavalent vaccine improves the relapse-free progression of urinary tract infections in children up to 87 % and is easy to use.